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INTRODUCTION
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and it accounts for 30% of leukemia-related deaths in children (1) . Current chemotherapy regimens ensure long-term remission only in 30 to 50% of patients and prognosis of relapsed cases is very poor, with a low survival probability (2, 3) . Therefore it is envisaged to develop novel alternative approaches for refractory patients. T-cell mediated immunotherapy using unmanipulated donor lymphocyte infusion (DLI) for the treatment of leukemia recurrence in hematopoietic stem cell transplant (HSCT) recipients, has had some success in AML, but the use of DLI carries a significant risk of inducing graft versus host disease (GvHD) (4) . Cytokine induced killer (CIK) cells are T lymphocytes enriched in CD3 + CD56
+ cells (5, 6) , that can be easily and rapidly expanded in vitro from either human peripheral blood, bone marrow or cord blood mononuclear cells (7, 8) with the sequential addition of IFN-, OKT-3 and high-doses of IL-2 (9, 10) . It has been demonstrated that CIK cells can lyse a broad array of tumor targets in a non-MHC-restricted manner (5, 9, 11) , have the capacity to migrate toward tumor sites (12, 13) and display anti-tumoral activity in vivo (9, 12) . On the contrary, they show negligible alloreactivity and minimal tendency to induce GvHD as compared to allogeneic splenocytes (14, 15) . The clinical applicability of CIK cells has been proved by various phase I studies performed so far (16) (17) (18) (19) , including our published experience, where we investigated the safety and toxicity profile of donorderived CIK cells in patients relapsing after allogeneic HSCT. Our study clearly indicated that good manufacturing practice (GMP)-grade allogeneic CIK cells generation and subsequent infusion are feasible and well tolerated. However, we registered only limited clinical responses (19) . Several reasons could be taken into account, but one of the most relevant might be related to the limited basal anti-leukemic activity of CIK cells, that showed, in in vitro testing, only a mean lytic activity of 40% against patients leukemic cells with a wide donor-dependent variability (19) . Moreover, since CIK cells are terminally differentiated T-effector memory CD45RA + (EMRA) lymphocytes (20) , they might have a restricted survival in vivo.
Therefore, novel strategies need to be conceived to increase CIK cells efficacy and persistence after injection. Chimeric receptors (CARs) represent an innovative technology to redirect T-cell activity against tumors. We previously demonstrated the potency of the CAR approach in redirecting CIK cells against B-lineage acute lymphoblastic leukemia (ALL) and we highlighted, as demonstrated by others (21, 22) , the crucial role exerted by costimulatory molecules in the CAR signalling domain, which significantly improve the antitumoral effector functions of CAR-expressing CIK cells. Furthermore, a recent study indicated that the inclusion of a tripartite CD28-OX40-ζ cytoplasmic domain into a CAR leads to a considerable higher proliferation and cytokine release of in vitro activated T cells (23) , than what observed with the CAR containing only one costimulatory domain. The so-called "third-generation" CARs might conceivably represent optimal constructs, as also recently shown in in vivo tumor models (24) .
With this study we aimed at improving CIK cells activity against AML through their genetic modification with two different CARs specific for the CD33 myeloid antigen, containing respectively the ζ or the CD28-OX40-ζ signalling domain. 
Generation of CIK cells
CIK cells were prepared as previously described (13) . Briefly, peripheral blood mononuclear cells (PBMCs) of healthy subjects were obtained after centrifugation of fresh blood on a density gradient using Ficoll-Hypaque (Pharmacia LKB, Uppsala, Sweden). Cells were then resuspended in complete advanced RPMI medium (Invitrogen, San Giuliano Milanese, Italy). At the beginning of the culture, IFN-γ (Dompè Biotec S.p.A, Milano, Italy) was added at 1000 U/ml. The next day, IL-2 (Chiron B.V, Emeryville, USA) and OKT-3 (Janssen-Cilag S.p.A., Cologno Monzese, Italy) were added at 300 U/ml and at 50 ng/ml, respectively, and cells were kept at the initial concentration of 3x10 6 cells/ml. Cells were then cultured for 21 days. Fresh medium and IL-2 were added weekly during culture and cell concentration was maintained around 0.5x10 6 cells/ml. 
Flow cytometric analysis

Chemotaxis and trans-Matrigel migration assays
Chemotactic migration assays were performed as previously described (13) 
Short-term cytotoxicity assay
The cytotoxicity of unmanipulated and anti-CD33.CARs-modified CIK cells against leukemic cells was evaluated as previously described (13) with a standard 4-hour 51 Chromium-release cytotoxicity assay. Radioactivity was detected by a β-scintillation counter (PerkinElmer Life Science, Boston, USA), as counts per minutes (CPM) and the percentage of specific lysis was calculated as previously described (27) . Experiments were performed in triplicates.
Long-term cytotoxicity assay
The killing activity of unmanipulated and anti-CD33.CARs-modified CIK cells toward leukemic cells was also determined after 6 day co-cultures in duplicates at 1:100 and at 1:200 effector:target (E:T) ratios, without exogenous IL-2, on a human bone-marrow derived stromal mesenchymal cell layer, as previously described (21) . After 6 days, cells were harvested, passed through a 19-gauge needle to disrupt residual mesenchymal-cell aggregates, stained with PE-anti-CD33 antibody and assayed by flow cytometry with a method specifically designed to enumerate leukemic cells recovered from culture, as previously described (21).
Cell proliferation assay
CD33-specific proliferation was evaluated by 3 H-thymidine (Amersham Pharmacia Biotech, Piscataway, USA) incorporation. 1x10 5 unmanipulated and anti-CD33.CARs-modified CIK cells were co-cultured for 72 hours with γ-irradiated HL-60 or primary AML cells, in triplicates at 1:1 E:T ratio, without the addition of IL-2. CPM were measured in a -scintillation counter (Beckman Coulter, LS6500 multipurpose scintillation counter, Brea, USA). Data are expressed as proliferation index (PI), calculated as the ratio of CPM stimulated/CPM unstimulated conditions. As a control, the same assay was performed using the CD33-negative SUP-B15 cell line. (28).
Statistical analysis
The results were compared by using the paired Student t test. A p value 0.05 was considered to be significant.
RESULTS -Generation and characterization of anti-CD33.CAR-transduced CIK cells
Healthy donor (HD)-derived CIK cells were efficiently generated and transduced with the SFG-anti-CD33-ζ and SFG-anti-CD33-CD28-OX40-ζ retroviral vectors, with a mean CAR expression after 21 days of culture of 64% and 65% (n=20), respectively ( Figure 1A and 1B -Anti-CD33.CAR-redirected CIK cells acquire potent lytic activity against different AML targets Anti-CD33.CARs-redirected CIK cells showed a strong cytotoxic activity in classical 4-hour 51 Chromium-release assays (shortterm cytotoxicity) against different CD33 + targets, including the HL-60 cell line (mean lysis, at E:T ratio of 5:1, 79%; n=7, for anti-CD33-ζ and mean lysis, 75%; n=7, for anti-CD33-CD28-OX40-ζ CIK cells), the KG-1 cell line (mean lysis, at E:T ratio of 5:1, 53%; n=4 for anti-CD33-ζ and mean lysis, 50%; n=4, for anti-CD33-CD28-OX40-ζ CIK cells), and primary AML samples (mean lysis, at 7 E:T ratio of 5:1, 61%; n=8 for anti-CD33-ζ and mean lysis, 65%; n=8, for anti-CD33-CD28-OX40-ζ CIK cells) ( Figure 3A ).
Cytotoxicity of anti-CD33.CARs-transduced CIK cells against AML cells was not dependent on CD33 expression levels and on the subtype of AML, with up to 100% of lysis even in case of CD33-low expressing AML cells ( Figure 3B ). On the contrary, unmanipulated cells were minimally cytotoxic against the same targets (mean lysis, at E:T ratio of 5:1, of HL-60, 28%; n=7; p 0.005; mean lysis, at E:T ratio of 5:1, of KG-1 cell line, 5%; n=4; p 0.005 and mean lysis, at E:T ratio of 5:1, of primary AML, 11%; n=8; p 0.005) ( Figure 3A) . were used as stimulators, except for IFN-γ, which was released at high levels also by unmanipulated CIK cells ( Figure 5B ), as previously described (30), a significant improvement in the production of TNF-α (n=6; p 0.05 for anti-CD33-ζ and n=6; p 0.05 for anti-CD33-CD28-OX40-ζ respectively), TNF-β (n=6; p 0.05 for CD33-ζ and n=6; p 0.05 for anti-CD33-CD28-OX40-ζ respectively), and IL-2 (n=4; p 0.05 for anti-CD33-ζ and n=4; p 0.05 for anti-CD33-CD28-OX40-ζ respectively) compared to unmanipulated CIK cells was detected in anti-CD33.CARs-expressing CIK cells, without major differences between the two receptors ( Figure 5B ).
-In vitro colony-forming capacity of normal hematopoietic progenitors is preserved after co-culture with anti-CD33.CAR-
transduced CIK cells
To assess the toxicity of anti-CD33.CAR-redirected CIK cells against normal CD34 n=3 and mean number of CFU-E+BFU-E, 52; n=3) ( Figure 6B ). Total numbers of colonies were, however, in the range of normality according to the assay utilized (31, 32) .
DISCUSSION
In this study we demonstrated that the introduction of anti-CD33-specific CARs into CIK cells is able to significantly improve their effector functions against AML cells in vitro, without affecting their native phenotype and characteristics. In particular, CIK cells acquired a considerably higher lytic activity, compared to unmanipulated cells, toward different AML cell lines and primary leukemic samples, including those with a more aggressive subtype. It is noteworthy that the killing efficiency was not dependent on CD33 expression level on target cells, as expected with the high-affinity 113-anti-CD33 scFv (33), thus suggesting that this approach might be very effective also in cases of low antigenic expression. We observed, as well, that anti-CD33.CARs-transduced CIK cells were able to maintain the anti-leukemic cytotoxicity over time in the absence of exogenous cytokines, as demonstrated by the 6-day co-culture assays at low E:T ratios and this phenomenon might be explained by their acquired CD33-specific proliferative potential. Moreover, the setting between the ζ-chain alone and "second generation" CARs containing the CD28-ζ and OX40-ζ domains separately, since many data have been already produced in the literature with these molecules (22) . Instead, we focused on a CAR containing a tripartite endodomain, based on the consideration that inclusion of a primary domain (ζ), an early signalling Ig superfamily member (CD28), with a later signalling TNF superfamily (OX40) member, could be considered an optimal construct to fully activate T cells (36) . In line with these considerations, it is interesting to note that the addition of the CD28-OX40 costimulatory endodomain to the anti-CD33-ζ.CAR significantly improved CIK cells effector functions that might be relevant to sustain the activity of anti-CD33.CAR-transduced CIK cells in vivo upon adoptive transfer, including CD33-specific proliferation and cytokine secretion. Besides, the benefit deriving from CD28-OX40 endodomain was particularly evident in the long-term cytotoxicity assay, which most likely reflects the potential clinical situation, where leukemic cells should be in numeric advantage over effector cells and no exogenous IL-2 is administered to the patient. The in vivo efficacy of a CAR-based approach could be knocked down by its immunogenicity: CARs are artificial proteins that might be abnormally processed and presented, thus generating new epitopes to which the immune system is not tolerant. However, the major cause of immunogenicity is likely to be represented by murine sequences present in the scFv domain of the CAR molecules: anti-CAR antibody responses have been seen with some CARs, but this could be encompassed by using humanized scFv or scFv derived from human monoclonal antibodies (22, 24, 36) , as we did in our study. who had also been previously treated with DLI, thus rendering impossible to dissect the real contribution of the two cell populations infused. Despite these limited results in terms of clinical efficacy, CIK cells still remain an interesting tool to be used for leukemia cell therapy, for the possibility to be simply generated and expanded to high numbers under GMP conditions, and for their low propensity to cause GvHD. Therefore, our proposed strategy was specifically designed to implement their capability to kill leukemia, but more importantly to persist through leukemia-specific proliferation and secretion of IL-2, and to further amplify the anti-leukemia response through IFN-γ, TNF-α and TNF-β release. Our results are very promising in this sense and might, at least partially, address the issue related to the limited efficacy of unmanipulated CIK cells observed in vivo in our previously published phase I study (19) .
The idea to target the CD33 molecule was first exploited by Gemtuzumab-Ozogamicin (GO), an anti-CD33 monoclonal antibody (mAb) conjugated with calicheamicin, which has shown in its clinical use a certain degree of activity, but also a suboptimal safety profile. Even though GO is highly effective as single treatment for patients with molecular relapse of acute promyelocytic leukemia (37), the complete response (CR) rate in AML, registered in different studies, is around 30% (38) . In addition, it has been reported that treatment with GO is associated with myelosuppression, neutropenia and thrombocytopenia, in almost all treated patients, and severe hepatotoxicity, with elevations of liver transaminases, hyperbilirubinemia and hepatic veno-occlusive disease, in approximately 20% of patients (38) . CAR-mediated cell therapy might have several potential advantages over GO. Anti-CD33.CAR-expressing CIK cells should be able, once infused, to better infiltrate the tumor and to exert a more physiological anti-leukemic response compared to GO, activating and intensifying a tumor-specific immune response, mediated only by the interaction with the CD33 antigen and subsequent T-cell mediated lysis, without addition of per se toxic chemotherapeutic agent. Moreover, CIK cells genetically modified with a CD33-specific CAR should avoid the drug-resistance mechanisms typical of GO, like dependence on CD33 expression levels (39) and capacity of the cells to internalize the drug or to mediate the efflux from the cells through P-glycoprotein (40, 41) . In this study, in fact, we demonstrated that anti-CD33.CARs-redirected CIK cells are able to kill at high levels the KG-1 cell line, known to be resistant to GO activity. In addition, we showed that cytotoxicity against all the CD33 + leukemic cells, differently from what described for GO, is not influenced by the expression intensity of CD33 on the targets, with strong lysis even in samples with low antigenic expression.
The use of CD33 as target antigen is not devoid of problems. This antigen, in fact, is expressed on the surface of normal hematopoietic precursors (myeloid, erythroid and megakaryocytic), and on Kuppfer cells. This panel of expression might partially explain the toxicity profile of GO. The CAR-CIK-based immunization strategy, instead, might have interesting advantages also on the safety profile. As we demonstrated in our study, in fact, even if anti-CD33.CARs-transduced CIK cells showed a significant killing against normal human hematopoietic progenitor cells, a reduced, but consistent, number of clonogenic progenitors were recovered in in vitro colony forming unit assays. This phenomenon could be explained by the fact that not all normal CD34 + CD38 -human hematopoietic progenitors express CD33 at their surface, as reported by Taussig et al. (42) . It is likely that these residual CD34 + CD33
stem cells, which will not be targeted by our treatment, will be enough to reconstitute the bone marrow compartment overtime. Anyway, we are well aware that only in vivo data could finally demonstrate the safety profile on normal hematopoietic progenitors. It is also to be noted that CIK cells could be further manipulated to introduce safety systems that might prevent undesired toxic effects or that might render cells rapidly eliminable from the organisms, in case of unwanted events occurrence. CIK cells, in fact, might be manipulated to prevent expression of adhesion molecule or chemokine receptors mediating migration/extravasation to the liver (43) or trough the introduction of a suicide gene. Many suicide gene systems are available (44), and we are currently comparing their efficacy (manuscript under preparation). Our preliminary data clearly show a potent and rapid clearance capacity of the inducible Caspase-9 system, which is at least equally effective as the Herpes Simplex Virus-Thymidine Kinase (HSV-TK) approach, it is clinically applicable (45) , and it presents the important advantage of being not immunogenic. Generally speaking, the addition of a suicide gene could be considered an ideal strategy to optimize the safety of our proposed approach. This system, in fact, can be exploited to prevent also the risks associated with the use of retroviral integrating vectors, that always raises concerns related to the described episodes of leukemia occurrence (46) .
However it is to be noticed that with terminally differentiated cells, as already widely discussed in other contexts, the likeliness of tumorigenic events is virtually absent (46) . Moreover, other kinds of transduction approaches are under evaluation, such as selfinactivating (SIN) vectors and non-viral methods (like transposones). Major technical developments are under constant investigation for a safer clinical translation (47) .
Finally, with this approach it is completely abrogated the CD33-independent toxicity caused by free calicheamicin, which is the main toxic mechanism due to GO. It has been described, in fact, that this toxin is accumulated in the hepatocytes inducing apoptosis and therefore significantly contributing to the hepatic damage (48) possibly greater toxic effects towards the normal hematopoietic compartment, and only in vivo data will finally solve this issue.
Noteworthy, in case of unwanted or limiting side effects, CAR-transduced cells can be potentially controlled by the mechanisms of safety-manipulation mentioned above.
Even though we are aware that we need to have final proof of the efficacy and safety of our anti-CD33.CARs-transduced CIK cells in a murine xenogenic model, that we are currently setting up, our results indicate that CD33-redirection of CIK cells might not only improve their effector functions against AML, but it also represents, when compared to the unmanipulated counterpart, a step forward in the immunotherapy of resistant and relapsed AML.
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